Last month, the United States Drug Enforcement Administration (DEA) placed Epidiolex, a proprietary oral solution of pure plant-derived cannabidiol (CBD), as a Schedule V drug of the Controlled Substances Act (CSA). This new placement is the least restrictive schedule of the CSA and much less restrictive than CBD’s Schedule 1 classification.Epidiolex’s recent approval from the Food and Drug Administration (FDA) permits GW Pharma (GWPH) to now market its CBD drug to the masses. This is the first FDA-approved drug that contains a purified drug substance derived from marijuana, another historic milestone recently reached for the marijuana industry. This move by the DEA takes a general glance at how the FDA is operating, placing “certain drug products that have been approved by the (FDA) and which contain (CBD) in schedule V of the Controlled Substances Act (CSA),” according to the DEA order. Although, Epidiolex is currently the only drug that meets the aforementioned criteria, numerous other companies in the space may be hopeful to the idea that these restrictions will diminish in the future. This news has recently generated increased investor attention to several marijuana stocks. Click Here For 3 Marijuana Stocks Targeting New Highs